Company news

AbCellera Biologics Inc. news in 2025

AbCellera Biologics Inc.'s news releases, calls and decks from 2025, newest first.

View company

AbCellera and Bruker Reach Global Settlement of Patent Litigation

December 17, 2025

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

December 7, 2025

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

November 9, 2025

AbCellera Reports Q3 2025 Business Results

November 5, 2025

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

October 6, 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

September 28, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

September 9, 2025

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

August 26, 2025

AbCellera to Participate at Upcoming Investor Conferences in September

August 11, 2025

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

August 6, 2025

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

July 6, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 29, 2025

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 13, 2025

AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 11, 2025

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025

AbCellera Reports Q1 2025 Business Results

May 7, 2025

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

April 28, 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

April 7, 2025

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

April 2, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

March 24, 2025

AbCellera Reports Full Year 2024 Business Results

February 26, 2025

AbCellera to Participate at Upcoming Investor Conferences in March

February 10, 2025

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

January 20, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

January 12, 2025

Calls in 2025

Decks in 2025